Answers are grounded in this paper and cite their sources.
The AVERT PRETERM trial (NCT03151330) evaluated whether screening clinically low-risk pregnancies with a validated maternal blood biomarker test for spontaneous preterm birth (sPTB) risk, followed by preventive treatments for those screening positive, would improve neonatal outcomes compared to a clinically low-risk historical population that had received the usual care. Prospective arm participants with singleton non-anomalous pregnancies and no PTB history were tested for sPTB risk at 19
No takes yet. Share an insight, caveat, or question.
Hoffman et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: